INDP vs. RLYB, BRNS, QTTB, LUMO, BIVI, JATT, SRZN, LEXX, OCX, and OKYO
Should you be buying Indaptus Therapeutics stock or one of its competitors? The main competitors of Indaptus Therapeutics include Rallybio (RLYB), Barinthus Biotherapeutics (BRNS), Q32 Bio (QTTB), Lumos Pharma (LUMO), BioVie (BIVI), JATT Acquisition (JATT), Surrozen (SRZN), Lexaria Bioscience (LEXX), OncoCyte (OCX), and OKYO Pharma (OKYO). These companies are all part of the "pharmaceutical products" industry.
Indaptus Therapeutics vs.
Rallybio (NASDAQ:RLYB) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, community ranking, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.
Rallybio received 29 more outperform votes than Indaptus Therapeutics when rated by MarketBeat users. However, 86.67% of users gave Indaptus Therapeutics an outperform vote while only 77.78% of users gave Rallybio an outperform vote.
Rallybio is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Rallybio's return on equity of -77.39% beat Indaptus Therapeutics' return on equity.
90.3% of Rallybio shares are held by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are held by institutional investors. 7.4% of Rallybio shares are held by insiders. Comparatively, 29.5% of Indaptus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Rallybio and Rallybio both had 1 articles in the media. Rallybio's average media sentiment score of 0.00 equaled Indaptus Therapeutics'average media sentiment score.
Rallybio has a beta of -1.48, meaning that its share price is 248% less volatile than the S&P 500. Comparatively, Indaptus Therapeutics has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500.
Rallybio presently has a consensus target price of $9.75, indicating a potential upside of 1,010.48%. Indaptus Therapeutics has a consensus target price of $8.50, indicating a potential upside of 863.72%. Given Rallybio's higher possible upside, equities research analysts clearly believe Rallybio is more favorable than Indaptus Therapeutics.
Summary
Rallybio beats Indaptus Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Indaptus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for INDP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Indaptus Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:INDP) was last updated on 1/21/2025 by MarketBeat.com Staff
